This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nölle, B. et al. Ann. intern. Med. 111, 28–40 (1989).
Lüdemann, J., Utecht, B. & Gross, W. L. J. exp. Med. 171, 357–362 (1990).
Niles, J.L. et al. Blood 74, 1888–1893 (1989).
Wilde, C.G. et al. J. biol. Chem. 265, 2038–2041 (1990).
Bories, D. et al. Cell 59, 959–968 (1989).
Jenne, D.E. & Tschopp, J. Immun. Rev. 103, 53–71 (1989).
Bogenberger, J. & Haas, M. Oncogene Res. 3, 301–312 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
JENNE, D., TSCHOPP, J., LÜDEMANN, J. et al. Wegener's autoantigen decoded. Nature 346, 520 (1990). https://doi.org/10.1038/346520a0
Published:
Issue Date:
DOI: https://doi.org/10.1038/346520a0
This article is cited by
-
Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study
Rheumatology International (2019)
-
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
Nature Reviews Rheumatology (2017)
-
ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients
Nature Reviews Rheumatology (2016)
-
Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis)
Seminars in Immunopathology (2013)
-
Clinical features of patients with anti-neutrophil cytoplasmic autoantibodies targeting native myeloperoxidase antigen
Modern Rheumatology (2013)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.